Amy E. Fraley is an Assistant Professor at ETH Zürich, Department of Chemistry and Applied Biosciences, and leads the Medicinal Chemistry Research Group. Her cross-disciplinary work bridges natural products biosynthesis, pharmaceutical sciences, and environmental sustainability through enzymatic chemistry and biotechnology. BSc in Chemistry, Millersville University of Pennsylvania (2014) PhD in Medicinal Chemistry, University of Michigan College of Pharmacy (2019) Postdoctoral work at ETH Zürich Institute of Microbiology under Prof. Jörn Piel Her research focuses on harnessing biosynthetic enzymes (e.g., halogenases, monooxygenases, Diels-Alderases) to create sustainable bioactive metabolites. She explores natural product biosynthesis in fungi and marine bacteria, targeting disease mechanisms and green chemistry applications. Recent work includes metagenomic studies of Lake Chilika microbial mats and polyketide synthase engineering. Notable scientific awards include the 2024 JSP Fellow at Bürgenstock Conference, 2018 Rackham Predoctoral Fellowship, and multiple University of Michigan honors. Her group secured funding from the ETH4D Doctoral Mentorship Grant and Messerli Foundation . Collaborations span structural biology, synthetic chemistry, and microbiology, with key contributions to flavoenzyme characterization and bioactive compound libraries . The lab emphasizes interdisciplinary training and innovation in biocatalytic tools for organic synthesis.
Gunnar Kusch is a Senior Research Associate at the Department of Materials Science & Metallurgy, University of Cambridge. His research focuses on defects in semiconductors, porous AlGaN materials, and advanced characterization techniques like cathodoluminescence (CL) and atom probe tomography (APT). He holds a PhD from the University of Strathclyde and leads projects on UV-B LED optimization, nanoscale defect behavior analysis, and semiconductor device design. His work bridges materials synthesis, characterization, and device performance, with applications in energy-efficient lighting and solar cell technology. Key research areas include: Defect engineering in III-nitride semiconductors Porous AlGaN templates for high-efficiency UV emitters Correlative microscopy techniques (CL, EBSD, APT) Composition-structure-property relationships in photovoltaic materials Notable contributions include developing CL-based methods for nanoscale defect analysis and demonstrating improved Cu(In,Ga)S₂ solar cell efficiencies through compositional engineering. His laboratory focuses on translating microscopic insights into macroscopic device improvements.
John E. Moses is a Professor at Cold Spring Harbor Laboratory (CSHL), where he leads the Moses Laboratory and serves as Faculty Head of the Mass Spectrometry Shared Resource for the Cancer Center. He is also a Cancer Center Member focusing on developing chemical tools for biological discovery, particularly in cancer research. Dr. Moses earned his D.Phil. in Synthetic Organic Chemistry from the University of Oxford in 2004. His academic journey includes positions as Professor of Organic Chemistry at La Trobe University (2017-2020), Level 6 Future Fellow at the Australian Research Council (2017-2021), and Reader & Associate Professor in Organic Chemistry at the University of Nottingham (2007-2017). Moses' research focuses on click chemistry, a powerful discovery method that uses robust chemical reactions to synthesize functional molecules. His lab specializes in developing and exploiting bond-forming click reactions for rapid synthesis of small functional molecules, including cancer drugs and chemical probes. They apply these molecular tools in multidisciplinary projects spanning biology and chemistry. His recent work has led to significant advances in click chemistry methodologies, including Diversity Oriented Clicking (DOC) and Phosphorus Fluoride Exchange (PFEx). These approaches have enabled the discovery of new cancer therapeutics and antibiotics effective against multidrug-resistant bacteria like MRSA. Dr. Moses has received numerous honors including the 2021 Organic Division Horizon Prize: Robert Robinson Award in Synthetic Organic Chemistry, Fellow of the Royal Society of Chemistry (2015), Thieme Chemistry Award (2011), and UK & ROI Lilly Award for Excellence in Organic Chemistry (2011). Through his work at CSHL, Moses mentors students and postdoctoral researchers while collaborating with biologists to develop Chemistry For Biology. His lab's innovative approaches have been supported by multiple grants, including those from the National Cancer Institute. The Moses Laboratory is at the forefront of click chemistry research, developing new methodologies while applying them to solve critical problems in cancer biology and antibiotic resistance.
Ashis K. Patra is a full-time Professor in the Department of Chemistry at the Indian Institute of Technology Kanpur (IIT Kanpur). After obtaining his Ph.D. from the Indian Institute of Science (IISc) Bangalore in 2008, he carried out post-doctoral research at Harvard University and the University of Georgia before joining IIT Kanpur in 2012. Education & Academic Training Ph.D. (2008), Indian Institute of Science (IISc), Bangalore M.Sc. (2002), The University of Burdwan Research Interests Professor Patra leads an interdisciplinary program that sits at the interface of inorganic chemistry, chemical biology, and medicinal chemistry. His work is organized into three principal thrusts: Therapeutic Applications of Metal Complexes: Design and mechanistic evaluation of cytotoxic transition-metal complexes that target nucleic acids and proteins, aiming to overcome multidrug resistance in cancer. Nitric Oxide Delivery from Transition Metal Nitrosyls: Development of photo- and redox-triggered metal nitrosyl complexes for controlled NO release to biological targets such as hemoglobin, myoglobin, and glutathione. Luminescent Lanthanide Complexes: Synthesis and photophysical characterization of Eu(III) and Tb(III) complexes that serve as luminescent probes and theranostic agents. Research Output & Impact His group has published extensively in leading journals including Dalton Transactions , Inorganic Chemistry , Chemical Science , and Journal of Inorganic Biochemistry . The collective work demonstrates a clear trajectory from fundamental coordination chemistry to translational applications in drug delivery and bioimaging, with recurring themes of redox control, light activation, and biological targeting. Scientific Awards & Fellowships CSIR Junior & Senior Research Fellowships (2001, 2003) West Bengal SLET Qualification (2001) International Travel Grants from CSIR & INSA (2006) DST Fast-Track Fellowship for Young Scientists (2013) Erasmus Mundus NAMASTE Scholarship for Academic Staff (2014) JSPS Invitation Fellowship (2016) Teaching & Mentoring Professor Patra teaches core and advanced courses in inorganic chemistry, including Inorganic Chemistry Laboratory, Bioinorganic Chemistry, and Frontiers in Inorganic Chemistry. He actively mentors Ph.D. and master’s students (full list available on his lab website ) and has established the Laboratory of Inorganic Chemical Biology in the Old Core Lab complex at IIT Kanpur.
Jun Liu is an Assistant Professor in the Department of Mechanical and Aerospace Engineering at the School of Engineering and Applied Sciences, University at Buffalo. His research focuses on advanced energy materials, nano/micro-mechanics, and self-powered systems, with applications in triboelectric energy harvesting and scanning probe microscopy. Education: PhD, Materials Engineering, University of Alberta (2018) MS, Materials Science, Shanghai University (2015) BE, Materials Science and Engineering, Nanchang University (2012) Research Interests: Development of tribovoltaic and triboelectric systems for self-powered electronics Mechanical energy harvesting via dynamic heterojunctions and Schottky contacts 3D-printed hydrogel structures for energy absorption and flexible electronics Nanoscale characterization using atomic force microscopy Design of nanocomposite sensors and catalytic materials Publication Trends: His work emphasizes triboelectricity, nanoscale energy conversion, and sustainable materials. Recent articles explore bionic tactile sensing, tunable hydrogels, and quantum dynamics in sliding interfaces. Awards: SONY Faculty Innovation Award (2021) Nature Springer MINE Young Scientist Award (2020) International Contest of Applications in Nano/Micro Technology Prize (2013) Laboratory: Advanced Energy Materials and Nanomechanics Lab at University at Buffalo.
Megan L. Matthews is an Assistant Professor in the Department of Chemistry at the University of Pennsylvania, School of Arts & Sciences, where she leads an active research group focused on chemical biology and enzymology. Her lab develops innovative chemical proteomics technologies to uncover novel enzyme cofactors and regulatory post-translational modifications, particularly those involving reactive electrophiles, which cannot be predicted from genomic sequences. B.S. in Chemistry, Miami University (2005) Ph.D. in Chemistry, The Pennsylvania State University (2011) Postdoctoral Fellow, The Scripps Research Institute (2012–2017) Her research centers on the concept of the 'electrophilome'—a largely unexplored half of the reactive proteome. By designing 'reverse-polarity' chemical probes, her group enables the discovery of functionally significant electrophilic modifications in proteins, especially those involved in cancer and Alzheimer’s disease. These discoveries open new avenues for therapeutic intervention through covalent targeting. The recent publications demonstrate a consistent focus on enzyme mechanisms, cofactor discovery, and chemical probe development. Her work spans from fundamental enzymology (e.g., halogenases, ribonucleotide reductases) to applied chemical biology (e.g., hydrazine probes, chemoproteomic profiling). The keywords across her publications highlight emerging themes in metalloenzymes, radical chemistry, and covalent proteome mapping. Her scientific contributions have been recognized through prestigious fellowships, including the Merck Helen Hay Whitney Postdoctoral Fellowship. She has published in top-tier journals such as Nature , Nature Chemical Biology , and Journal of the American Chemical Society . Dr. Matthews advises graduate students and postdoctoral researchers in her lab, fostering a collaborative and inclusive environment. Her lab emphasizes the importance of diverse perspectives in scientific discovery. She has secured research funding to support projects in probe development, target characterization, and disease mechanism studies, particularly in neurodegenerative diseases and cancer. The Matthews Lab is actively engaged in advancing reverse-polarity activity-based protein profiling (RP-ABPP) for in vivo applications and inhibitor screening. The group collaborates with experts in structural biology, spectroscopy, and disease modeling to translate basic discoveries into therapeutic insights.
Kathrin Lang is a Full Professor at the Department of Chemistry and Applied Biosciences, ETH Zurich, and Head of the Organic Chemistry Laboratory. Her research focuses on chemical biology, particularly the development of tools for genetic code expansion to incorporate non-canonical amino acids into proteins and advance bioorthogonal chemistries for studying biological processes. Keywords: Genetic Code Expansion, Bioorthogonal Chemistry, Protein Engineering, Ubiquitylation Networks, Post-Translational Modifications. Lang’s work emphasizes proximity-triggered crosslinking reactions, bioorthogonal labeling, and in vivo chemistries to address challenges in protein interaction mapping and structural elucidation. Her group’s recent publications highlight methodologies for dual protein labeling, deciphering ubiquitin code, and enhancing cycloaddition reactivity. Current projects include exploring cyclopropene-fused dibenzocyclooctynes for improved labeling and investigating methylated lysine as a conformational regulator in Hsp90. Funding sources include the ERC (Ubl-tool), DFG (SFB1035, SPP1926), and ETH Zurich. She contributes to education through courses like Genetic Code Expansion for Studying Posttranslational Modifications and Chemical Biology and Synthetic Biochemistry . Collaborative efforts span structural biology, microbiology, and synthetic biochemistry, with applications in ubiquitin research and cellular imaging.
Raphael Franzini serves as Associate Professor of Medicinal Chemistry at the University of Utah, actively contributing to the Biological Chemistry PhD Program. His research pioneers innovative chemical approaches for therapeutic development, with dual focus on DNA-encoded library technologies and bioorthogonal drug delivery systems. His educational foundation includes an M.S. from the Swiss Federal Institute of Technology (Lausanne) and a Ph.D. from Stanford University. This training underpins his group's multidisciplinary methodology combining organic synthesis, bioconjugation, computational modeling, and advanced imaging techniques. Dr. Franzini's research program centers on two transformative areas: First, advancing DNA-encoded library screening through computational integration to identify leads for challenging targets like Tankyrase and Sirtuin 6, with recent work addressing false negatives in machine learning prediction. Second, developing novel bioorthogonal release chemistry using isonitrile-tetrazine reactions for spatiotemporally controlled drug activation, validated in zebrafish models. His group emphasizes both technological innovation and therapeutic translation, with chemistry designed to minimize off-target effects in solid tumors. Analysis of his 15 most recent publications reveals escalating integration of computational methods with experimental library screening, alongside refinement of bioorthogonal release kinetics. The work spans chemical biology, medicinal chemistry, and pharmaceutical sciences, with growing emphasis on machine learning for library data interpretation and in vivo validation of drug-release systems. Dr. Franzini maintains an active research laboratory that provides comprehensive training in cutting-edge drug discovery methodologies. His group culture prioritizes both scientific innovation and researcher development, with projects spanning from fundamental reaction kinetics to therapeutic applications. The lab's infrastructure supports organic synthesis, molecular imaging, and computational analysis for advancing precision therapeutics.
Juliane Nguyen, PhD, is a Professor in the Department of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. She serves as Vice Chair and Director of Graduate Admissions in her department and holds an adjunct appointment as Professor of Biomedical Engineering. Dr. Nguyen is also a member of the UNC Lineberger Comprehensive Cancer Center, where she applies molecular engineering approaches to develop innovative therapeutic solutions. Dr. Nguyen's research focuses on molecular engineering to advance protein-based therapeutics, live biotherapeutics (including engineered probiotic yeast), and extracellular vesicles. Her lab develops cutting-edge technologies to treat diverse conditions including cancer, myocardial infarction, chemotherapy-induced cardiotoxicity, and inflammatory bowel diseases. Her interdisciplinary approach integrates molecular engineering, pharmaceutical sciences, and bioinformatics to create complex biologics with exceptional safety and efficacy profiles. Key research areas include developing therapeutics for cardiac repair, genetically encoded materials targeting tumor-associated macrophages, live biotherapeutics for inflammatory bowel diseases using engineered probiotic yeast, and auxetic patches for dynamic organ repair. Analysis of Dr. Nguyen's recent publications reveals a strong focus on translational research with significant contributions to cardiac repair technologies, cancer immunotherapy, inflammatory bowel disease treatments, and advanced biomaterials. Her work consistently bridges fundamental molecular engineering with clinical applications, particularly in the areas of targeted drug delivery, extracellular vesicle therapeutics, and engineered live biotherapeutics. The research demonstrates a clear trajectory toward developing clinically viable solutions for previously challenging medical conditions. Dr. Nguyen has received numerous prestigious awards and honors including the NSF CAREER Award (2018), Eshelman Innovation Award (2020), and recognition as a Fellow of the Controlled Release Society (2023). She was appointed as a Standing Member of the NIH Drug and Biologic Therapeutic Delivery Study Section (2023-2025) and serves as Executive Editor of Advanced Drug Delivery Reviews since 2021. Her Galenus Guest Professorship at ETH Zuerich (2024) and keynotes at major conferences highlight her international recognition in the field. As Director of Graduate Admissions and an active mentor, Dr. Nguyen has advised numerous PhD and Master's students who have co-authored significant publications with her. Her research is supported by competitive grants including the NSF CAREER Award and other NIH-funded projects. The Nguyen Lab maintains strong collaborations across disciplines, particularly with cardiology, oncology, and biomedical engineering researchers. She leads an interdisciplinary team focused on translating molecular engineering breakthroughs into clinically impactful therapies. The Nguyen Lab operates as a dynamic, interdisciplinary research environment combining expertise in molecular engineering, pharmaceutical sciences, and bioinformatics. The lab's mission is to revolutionize medicine by developing next-generation therapeutics that target diseases at the molecular level. Current projects focus on translating cutting-edge research into life-changing therapies for patients suffering from cancer, myocardial infarction, colitis, and other challenging conditions. The lab's innovative approach to biomolecular engineering positions it at the forefront of developing safe, effective, and personalized therapeutic solutions.
Thomas Winkler is an Associate Professor at the Division of Micro and Nanosystems, KTH Royal Institute of Technology, Sweden, and collaborates with TU Braunschweig, Germany. His research focuses on solving life science challenges using microsystems tools, particularly in neuropsychiatric disorders like schizophrenia. He develops organ-on-chip models, engineered microfluidic platforms, and biosensors for point-of-care diagnostics. Winkler leads an interdisciplinary ERC-funded team addressing metabolic coupling in neurovascular units and oxidative stress biomarkers. Key achievements include the ERC Starting Grant (2023) and work on electrochemical sensors for clozapine monitoring. He teaches courses such as Microsystem Technology (EK2350) and supervises PhD and postdoctoral researchers. Current projects include machine learning-guided robotic organoid maturation and electrochemical technology development for the CHIPzophrenia initiative. His lab actively seeks talent through open positions in Stockholm and Braunschweig. Scientific awards include the ERC Starting Grant and Marie Skłodowska-Curie Actions Fellowship. Research spans sensor development, microfabrication, and biomaterials, with a focus on translating lab technologies to clinical applications. Collaborations bridge engineering and life sciences, emphasizing personalized mental healthcare solutions.
Christoph Bostedt holds dual appointments as a Professor of Physical Chemistry at the Ecole Polytechnique Fédérale de Lausanne (EPFL) and as Head of the Laboratory for Synchrotron Radiation and Femtochemistry (LSF) at the Paul Scherrer Institut (PSI). He leads strategic operations for the LSF, managing five research groups and overseeing four beamlines at the Swiss Light Source and the Alvra Endstation at SwissFEL. His research focuses on ultrafast x-ray science, including single-shot imaging, non-linear x-ray spectroscopy, and femtosecond pump-probe techniques. He collaborates globally on initiatives like the Athos project, aiming to advance ultrafast x-ray technologies. Bostedt has over 150 publications and is a Fellow of the American Physical Society, recipient of the Röntgen Prize. Education: Ph.D. from the University of Hamburg with research at Lawrence Livermore and Berkeley National Laboratories. Prior roles include leadership at Argonne National Laboratory and SLAC National Accelerator Laboratory. Research Interests: Single-particle imaging and coherent diffraction X-ray free-electron laser applications Ultrafast dynamics in nanoparticles and molecular systems Non-linear x-ray spectroscopy Time-resolved x-ray pump-probe methods Awards: Fellow of the American Physical Society Röntgen Prize (University of Giessen) Labs & Projects: Spearheads the Athos beamline project at SwissFEL, developing the Maloja endstation for ultrafast x-ray studies. Oversees the Laboratory for Femtochemistry and collaborates on advanced imaging techniques for nanoscale science.
Christopher J. Chang is the Edward and Virginia Taylor Professor of Bioorganic Chemistry at Princeton University's Department of Chemistry. His research focuses on chemical biology, catalysis, and inorganic chemistry, with an emphasis on transition metal signaling, activity-based sensing, and drug discovery. He leads the Chang Lab, which develops innovative chemical tools to study metal-dependent biological processes, including copper's role in neurobiology and cancer, formaldehyde's role in epigenetic regulation, and redox-driven protein function. His work integrates organic, inorganic, and biological chemistry, enabling discoveries in imaging, proteomics, and precision medicine. Notable achievements include pioneering activity-based sensing platforms for copper and reactive metabolites, revealing metalloplasia in cancer, and developing copper-specific therapies. Christopher Chang has received over 50 prestigious awards, including the Guggenheim Fellowship and the Howard Hughes Medical Institute Investigatorship. His lab's infrastructure includes advanced analytical instruments, synthetic chemistry facilities, and cell culture capabilities, supported by grants from NIH, NSF, and industry partnerships. Awards: ACS Bader Award (2024), Ivano Bertini Award (2022), Blavatnik National Award (2015) Lab Focus Areas: Transition metal signaling, copper-dependent biology, formaldehyde metabolism, redox drug discovery Key Technologies: Activity-based sensors, imaging probes, bioconjugation methods
Professor Ali Gilles Tchenguise Miserez holds a joint appointment as Professor in the School of Materials Science and Engineering and the School of Biological Sciences at Nanyang Technological University (NTU) in Singapore. He is also the President's Chair in Materials Science and Engineering. His research group, the Biological and Biomimetic Materials Laboratory (BBML), is highly interdisciplinary, bringing together molecular biologists, chemists, bio-physicists, and materials scientists to study natural materials with unique properties not found in man-made materials. Prof. Miserez's research interests span multiple areas including bioelastomeric membranes & coiled-coil engineering, mechanisms of biofouling adhesion & anti-adhesive coatings, molecular biomimetics of non-mineralized hard tissues, biomineralized structures with graded properties, and liquid-liquid phase separation. His work focuses on understanding the molecular, physico-chemical, and structural principles of biological materials and translating these designs into novel biomimetic synthesis strategies. His laboratory emphasizes "green chemistry" approaches that mimic nature's energy-efficient synthesis methods under ambient conditions. Prof. Miserez's publication record demonstrates significant impact across multiple disciplines, with work appearing in top journals including Science, Nature Materials, Nature Biotechnology, Nature Chemical Biology, and Advanced Materials. His recent research has particularly focused on peptide coacervates for intracellular delivery of therapeutics, with applications in cancer treatment, mRNA delivery, and nucleic acid therapeutics. This work represents a convergence of materials science, biochemistry, and medicine with significant translational potential. Singapore National Research Foundation (NRF) Fellowship (2011) - $3 Million individual research grant for early career scientists Prof. Miserez has mentored numerous PhD students and postdoctoral researchers, many of whom have gone on to successful careers in academia and industry. His laboratory has developed strong international collaborations and has secured significant research funding. Current projects include developing peptide-based delivery systems for cancer therapeutics, understanding marine biofouling mechanisms, and creating biomimetic materials inspired by natural systems. The BBML laboratory is actively recruiting talented researchers interested in interdisciplinary work at the interface of biology and materials science.
Brent Page is an Associate Professor (tenured) in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) and maintains a research group at the Karolinska Institute , Department of Oncology and Pathology. His dual affiliation underpins a trans-Atlantic program that integrates cutting-edge chemical biology with medicinal chemistry for anti-cancer drug discovery. Education & Training PhD in Chemistry – University of Toronto (2013) HBSc in Chemistry (Honours) – University of British Columbia (2008) CIHR Postdoctoral Fellow – Karolinska Institute, Sweden (2008–2016) Assistant Professor (non-independent) – Karolinska Institute, Department of Oncology-Pathology (2017–2021) Research Focus Dr. Page’s laboratory operates at the interface of medicinal chemistry and chemical biology , aiming to identify and optimize small-molecule inhibitors for proteins previously considered “undruggable.” Core targets include STAT3, CLIC3, NUDT5/15 and SRPK3 . The group employs cellular thermal shift assays , isothermal ligand-induced resolubilization (ILIRA) , and CeTEAM technologies to quantify target engagement and refine structure–activity relationships in physiologically relevant models of breast cancer, triple-negative breast cancer, leukemia and atopic diseases . Funding & Collaborations His program is supported by Canadian Institutes of Health Research (CIHR) and other national and international agencies. Dr. Page actively participates in UBC’s Accelerated Translational Opioid Research Cluster and welcomes interdisciplinary collaborations and undergraduate research involvement. Equity, Diversity & Inclusion Committed to fostering an inclusive environment, Dr. Page mandates EDI training for all lab members and actively encourages participation from equity-deserving groups.
James Shorter is a Professor of Biochemistry and Biophysics at the Perelman School of Medicine, University of Pennsylvania. He is affiliated with multiple prestigious institutes, including the Institute on Aging (IOA), the Institute for Translational Medicine and Therapeutics (ITMAT), the Penn Center for AIDS Research (CFAR), the Chemistry-Biology Interface (CBI), and the Penn Institute for RNA Innovation. He mentors several training programs such as the Penn Summer Undergraduate Internship Program (SUIP), PennPREP, and the Translational Research Immersion Program (TRIP), and serves as a Primary Trainer at the Center for Neurodegenerative Research (CNDR). Ph.D. in Cell Biology, University of London, 2000 M.A. in Biology, University of Oxford, 1995 Dr. Shorter’s research focuses on protein homeostasis, particularly the mechanisms of protein disaggregation and the role of prion-like domains in neurodegenerative diseases such as ALS, Alzheimer’s, Parkinson’s, and frontotemporal lobar degeneration. His lab investigates the Hsp104 disaggregase from yeast and has engineered variants to combat human proteinopathies. They also identified the mammalian disaggregase system (Hsp110/Hsp70/Hsp40) and explore how small molecules and nuclear import receptors can reverse pathological phase transitions of RNA-binding proteins like TDP-43 and FUS. His work bridges structural biology, genetics, and translational neuroscience. His recent publications highlight trends in targeting TDP-43 and FUS proteinopathies, engineering Hsp104 for selective detoxification, understanding mitochondrial disaggregases like Skd3, and modulating phase transitions with nuclear import receptors. His research spans from fundamental mechanisms of protein folding to therapeutic development for neurodegenerative diseases. Faculty Member, Institute on Aging (IOA) Faculty Member, Institute for Translational Medicine and Therapeutics (ITMAT) Mentor, Penn Summer Undergraduate Internship Program (SUIP) Primary Trainer, Center for Neurodegenerative Research (CNDR) Faculty Member, Penn Center for AIDS Research (CFAR) Member, Penn Institute for RNA Innovation Mentor, Translational Research Immersion Program (TRIP) Dr. Shorter advises numerous graduate students and postdoctoral researchers through the Biochemistry and Molecular Biophysics, Pharmacology, Neuroscience, and Cell and Molecular Biology graduate groups. His lab receives funding from NIH and other sources to support research on protein disaggregation, phase separation, and neurodegenerative disease mechanisms. He has trained many scientists now active in academia and biotech. His lab, located in Stellar-Chance Laboratories, operates at the intersection of biochemistry, cell biology, and translational medicine, with active projects on Hsp104 engineering, mitochondrial proteostasis, and the role of RNA-binding proteins in disease. The lab collaborates widely across Penn and with international partners to advance understanding and treatment of protein misfolding disorders.
